January 2024 Test Bulletin

January 16, 2024

Alverno's January 2024 Test Bulletin provides crucial updates for healthcare providers. It announces the suspension of quantitative reporting for Midazolam and Doxepin metabolites, issues with the Platelet Antibody IgG test, discontinuation of certain Quest tests, transition of STI testing to the Abbott Alinity m platform, and updates to Quest specimen stability. These changes aim to ensure testing accuracy, improve specimen collection, and maintain quality standards for patient care.